To discover structurally different CDK2 inhibitors with improved potency and selectivity, we have designed, synthesized, and evaluated trisubstituted pyrimido[4,5-d]pyrimidines as inhibitors of tumor cell proliferation. The gene discussed is CDK2; the disease is neoplasm.